

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck ID1140

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Merck Sharpe & Dohme (pembrolizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Black Health Agency Cancer Black Care Cancer Equality Cancer Laryngectomy Trust Cancer52 Changing Faces Get-A-Head HAWC Helen Rollason Cancer Charity Independent Cancer Patients Voice Let's Face it Macmillan Cancer Support Maggie's Centres Marie Curie Mouth Cancer Foundation Muslim Council of Britain National Association of Laryngectomy Clubs Specialised Healthcare Alliance South Asian Health Foundation Swallows Head & Neck Cancer Support Group Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Cancer Physicians British Association of Head and Neck Oncologists British Association of Oral and Maxillofacial Surgeons British Association of 	<p><u>General</u></p> <ul style="list-style-type: none"> Allied Health Professionals Federation All Wales Therapeutics and Toxicology Centre Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association for Primary Care National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> Accord Healthcare (carboplatin, cisplatin, fluorouracil) Almirall (fluorouracil) Consilient Health (fluorouracil) Hospira UK (carboplatin, cisplatin, fluorouracil) Medac GmbH (fluorouracil) Merck (cetuximab) Sandoz (cisplatin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> Cochrane Ear, Nose and Throat Disorders Group

Final matrix for the appraisal of pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck ID1140

Consultees	Commentators (no right to submit or appeal)
<p>Otorhinolaryngologists</p> <ul style="list-style-type: none"> • British Dental Health Foundation • British Dietetic Association – Oncology Specialist Group • British Geriatrics Society • British Institute of Radiology • British Oculoplastic Surgery Society • British Psychosocial Oncology Society • British Skull Base Society • Cancer Research UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Oxfordshire CCG • NHS South Gloucestershire CCG • Welsh Government 	<ul style="list-style-type: none"> • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Oracle Cancer Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.